Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages 649-657

  Vélayoudom Céphise, Fritz Line ^a   Duvillard, Pierre ^b   Foucan, Lydia ^c   Hadoux, Julien ^a   Chougnet, Cecile N ^a   Leboulleux, Sophie ^a   Malka, David ^a   Guigay, Joël ^a,e   Goere, Diane ^d   Debaere, Thierry ^b   Caramella, Caroline ^b   Schlumberger, Martin ^a   Planchard, David ^a,e   Elias, Dominique ^d   Ducreux, Michel ^a,e   Scoazec, Jean Yves ^b   Baudin, Eric ^a  

^a Department of Nuclear Medicine and Endocrine Oncology ^*  (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c University of Antilles and Guyane   (Guadeloupe)

^d Digestive Surgery   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Carcinoma; Grade 3 neuroendocrine; Ki67 index; Mitotic count; WHO classification

Indexed keywords

CHROMOGRANIN A; CISPLATIN; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; SOMATOSTATIN RECEPTOR; SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TRACT SCINTISCANNING; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; MALE; MITOSIS INDEX; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR NECROSIS;

EID: 84886439997     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0027     Document Type: Article

References (33)

1. Abgral R, Leboulleux S, Deandreis D, Auperin A, Lumbroso J, Dromain C, Duvillard P, Elias D, de Baere T, Guigay J et al. 2011 Performance of (18) fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (O/Z10%) well-differentiated endocrine carcinoma staging. Journal of Clinical Endocrinology and Metabolism 96 665-671. (doi:10.1210/jc.2010-2022)
2. Baudin E 2007 Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nature Clinical Practice. Endocrinology & Metabolism 3 228-239. (doi:10.1038/ncpendmet0425)
3. Baudin E,GigliottiA, DucreuxM, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffie P et al. 1998 Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. British Journal of Cancer 78 1102-1107. (doi:10.1038/bjc.1998.635)
4. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M et al. 2005 Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. Journal of Clinical Oncology 23 70-78. (doi:10.1200/JCO.2005.01.013)
5. Durante C, Boukheris H, Dromain C, Duvillard P, Leboulleux S, Elias D, de Baere T, Malka D, Lumbroso J, Guigay J et al. 2009 Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocrine-Related Cancer 16 585-597. (doi:10.1677/ERC-08-0301)
6. Ekeblad S, Skogseid B, Dunder K, Oberg K & Eriksson B 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical Cancer Research 14 7798-7803. (doi:10.1158/1078-0432.CCR-08-0734)
7. Faggiano A, Sabourin JC, DucreuxM, Lumbroso J, Duvillard P, Leboulleux S, Dromain C, Colao A, SchlumbergerM& Baudin E 2007 Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas: diagnostic and prognostic features. Cancer 110 265-274. (doi:10.1002/cncr.22791)
8. Hainsworth JD, Spigel DR, Litchy S & Greco FA 2006 Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology 24 3548-3554. (doi:10.1200/JCO. 2005.05.0575)
9. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P, Maire F, O'Toole D, Levy P, Sauvanet A et al. 2011 Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocrine-Related Cancer 18 51-59. (doi:10.1677/ ERC-09-0319)
10. Jann H, Roll S,Couvelard A, Hentic O, PavelM, Muller-Nordhorn J, KochM, Rocken C, Rindi G, Ruszniewski P et al. 2011 Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117 3332-3341. (doi:10.1002/cncr. 25855)
11. Leboulleux S, Dromain C, Vataire AL, Malka D, Auperin A, Lumbroso J, Duvillard P, Elias D, Hartl DM, De Baere T et al. 2008 Prediction and diagnosis of bone metastases in well-differentiated gastro-enteropancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. Journal of Clinical Endocrinology and Metabolism 93 3021-3028. (doi:10.1210/jc.2008-0459)
12. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C & Faivre J 2004 Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut 53 549-553. (doi:10.1136/gut. 2003.026401)
13. Lim E, Yap YK, De Stavola BL, Nicholson AG & Goldstraw P 2005 The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. Journal of Thoracic and Cardiovascular Surgery 130 969-972. (doi:10.1016/j.jtcvs.2005.05.041)
14. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P & Ruszniewski P 1998 Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 422-427. (doi:10.1136/gut.43.3.422)
15. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M et al. 1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 81 1351-1355. (doi:10.1038/sj.bjc.6690325)
16. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
17. Moertel CG, Kvols LK, O'Connell MJ & Rubin J 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 227-232. (doi:10.1002/1097- 0142(19910715) 68:2!227::AID-CNCR2820680202O3.0. CO;2-I)
18. Niederle MB, Hackl M, Kaserer K & Niederle B 2010 Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on theWHOand European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocrine- Related Cancer 17 909-918. (doi:10.1677/ERC-10-0152)
19. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P et al. 2011 Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. Journal of Clinical Oncology 29 2372-2377. (doi:10.1200/JCO.2010.33.0688)
20. Pape UF, BerndtU,Muller-Nordhorn J, BohmigM, Roll S, KochM,WillichSN &Wiedenmann B 2008 Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 15 1083-1097. (doi:10.1677/ERC-08-0017)
21. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B & Salazar R 2012 ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95 157-176. (doi:10.1159/000335597)
22. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C & Solcia E 1999 ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116 532-542. (doi:10.1016/S0016-5085(99) 70174-5)
23. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. 2006 TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 449 395-401. (doi:10.1007/s00428-006-0250-1)
24. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A et al. 2007 TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 451 757-762. (doi:10.1007/s00428-007-0452-1)
25. Rindi G, Klimstra DS, Arnold R, Kloppel G, Bosman FT, Komminoth P, Capella C & Solcia E 2010 Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In WHO Classification of Tumours of the Digestive System, pp 13-14. Eds FT Bosman, F Carneiro, RH Hruban & ND Theise. Lyon: IARC.
26. Solcia E, Klppel G, Sobin LH &Williams ED 2000 Histological typing of endocrine tumours. 2nd edn, pp 61-68. New York, NY, USA: Springer-Verlag.
27. Strosberg J, Gardner N & Kvols L 2009 Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 38 255-258. (doi:10.1097/MPA.0b013e3181917e4e)
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205-216. (doi:10.1093/jnci/92.3.205)
29. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA & Koss MN 1998 Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. American Journal of Surgical Pathology 22 934-944. (doi:10.1097/00000478- 199808000-00003)
30. Travis WD CT, Corrin B, Shimosato Y & Brambilla E 1999 In collaboration with Sobin LH and pathologists from 14 countries. World Health Organization International Histological Classification of Tumours. Histological Typing of Lung and Pleural Tumours, 3rd edn. Springer-Verlag.
31. Yamazaki S, Sekine I,Matsuno Y, Takei H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T,KodamaT, AsamuraHet al. 2005Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 49 217-223. (doi:10.1016/j.lungcan.2005.01.008)
32. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
33. Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A & Oberg KE 2011 Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism 96 3741-3749. (doi:10.1210/jc.2011-0666)